Lenalidomide Grindeks (Lenalidomide)

Lenalidomide is used in hematologic malignancies by targeting abnormal plasma cells and related disease pathways.

• Multiple myeloma: reduces tumor burden and prolongs progression‑free survival.
• Myelodysplastic syndromes with 5q deletion: improves blood counts and reduces transfusion dependence.
• Mantle cell lymphoma: induces remission and extends overall survival.
• Relapsed/refractory multiple myeloma: provides an additional therapeutic option after prior treatments.

• Lenalidomide binds to the cereblon subunit of the CRL4‑CRBN E3 ubiquitin ligase complex. This interaction alters substrate specificity, leading to ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). The loss of these factors suppresses tumor‑cell proliferation, reduces angiogenesis, and enhances T‑cell and natural‑killer cell mediated immune responses against malignant cells. Additionally, it modulates cytokine production, contributing to its immunomodulatory profile.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools that may lead to dehydration.
• Rash: skin redness or mild itching.
• Thrombocytopenia: reduced platelet count leading to easy bruising.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: markedly low neutrophil count increasing infection risk.
• Secondary primary malignancies: emergence of new cancers unrelated to original disease.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.
• Severe infections: opportunistic or life‑threatening bacterial, viral, or fungal infections.
• Life‑threatening cutaneous reactions (e.g., Stevens‑Johnson syndrome).

Before initiating lenalidomide therapy, several safety considerations should be reviewed.

• Blood count monitoring: perform baseline and regular CBC to detect neutropenia or thrombocytopenia.
• Thromboembolic risk assessment: evaluate need for prophylactic anticoagulation in high‑risk patients.
• Pregnancy avoidance: prescribe effective contraception for both male and female patients of reproductive potential.
• Renal function adjustment: modify dose in patients with impaired renal clearance.
• Drug interaction review: check concomitant medications that may alter lenalidomide exposure.
• Store below 25°C: keep in the original packaging, protect from moisture and direct light.

Lenalidomide interacts with several agents that can affect its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce lenalidomide plasma concentrations.
• Concurrent anticoagulants (warfarin, direct oral anticoagulants): increase risk of serious bleeding events.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise lenalidomide levels, requiring dose adjustment.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): elevate risk of gastrointestinal bleeding when combined with anticoagulants.
• Live vaccines: reduced efficacy and potential for infection; avoid during therapy.